Modifier Genes as Therapeutics: The Nuclear Hormone Receptor Rev Erb Alpha (Nr1d1) Rescues Nr2e3 Associated Retinal Disease
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Nuclear hormone receptors play a major role in many important biological processes. Most nuclear hormone receptors are ubiquitously expressed and regulate processes such as metabolism, circadian function, and development. They function in these processes to maintain homeostasis through modulation of transcriptional gene networks. In this study we evaluate the effectiveness of a nuclear hormone receptor gene to modulate retinal degeneration and restore the integrity of the retina. Currently, there are no effective treatment options for retinal degenerative diseases leading to progressive and irreversible blindness. In this study we demonstrate that the nuclear hormone receptor gene Nr1d1 (Rev-Erbα) rescues Nr2e3-associated retinal degeneration in the rd7 mouse, which lacks a functional Nr2e3 gene. Mutations in human NR2E3 are associated with several retinal degenerations including enhanced S cone syndrome and retinitis pigmentosa. The rd7 mouse, lacking Nr2e3, exhibits an increase in S cones and slow, progressive retinal degeneration. A traditional genetic mapping approach previously identified candidate modifier loci. Here, we demonstrate that in vivo delivery of the candidate modifier gene, Nr1d1 rescues Nr2e3 associated retinal degeneration. We observed clinical, histological, functional, and molecular restoration of the rd7 retina. Furthermore, we demonstrate that the mechanism of rescue at the molecular and functional level is through the re-regulation of key genes within the Nr2e3-directed transcriptional network. Together, these findings reveal the potency of nuclear receptors as modulators of disease and specifically of NR1D1 as a novel therapeutic for retinal degenerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that modifier genes, such as nuclear hormone receptors, have the potential to “reset” various networks related to retinal disease phenotypes, such as photoreceptor development, phototransduction, metabolism, cone cell development, inflammation, and cell survival, thus restoring the homeostasis in the retina to a healthy state.47,50–53”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modifier gene therapy has the potential to alter the retinal disease state even in the absence of a genetic diagnosis or in the absence of a gene therapy specific to the mutated gene in one of these patients.47,50–53”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Electroporation and RNA interference in the rodent retina in vivo and in vitro
Matsuda, T., & Cepko, C. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235688100 · Cited by 1,029
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Nuclear Receptor Rev-erbα Is a Critical Lithium-Sensitive Component of the Circadian Clock
Yin, L., Wang, J., Klein, P. S., & Lazar, M. A. (2006) · Science · doi:10.1126/science.1121613 · Cited by 556
Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Haider, N. B., Jacobson, S. G., Cideciyan, A. V., Swiderski, R., Streb, L. M., Searby, C., Beck, G., Hockey, R., Hanna, D. B., Gorman, S., et al. (2000) · Nature Genetics · doi:10.1038/72777 · Cited by 507
Self-citationStorch, K.-F., Paz, C., Signorovitch, J., Raviola, E., Pawlyk, B., Li, T., & Weitz, C. J. (2007) · Cell · doi:10.1016/j.cell.2007.06.045 · Cited by 460 · cited 2×
“In the retina, both Nr2e3 and Nr1d1 mRNA levels oscillate over a 24-hour period [45].”
BackgroundCideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Pang, J.-J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.086 · Cited by 312
Modifier genes in Mendelian disorders: the example of cystic fibrosis
Cutting, G. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05879.x · Cited by 271
Peng, G.-H., Ahmad, O., Ahmad, F., Liu, J., & Chen, S. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi070 · Cited by 270
Cited by
From Peas to Disease: Modifier Genes, Network Resilience, and the Genetics of Health
Riordan, J. D., & Nadeau, J. H. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.004 · Cited by 168
“Fine-mapping of a candidate protective locus led to the identification of Nr1d1 (nuclear receptor subfamily 1, group D, member 1) as a modifier gene whose increased expression compensates for loss of Nr2e3 to eliminate the disease phenotype.(93) Nr1d1 encodes the nuclear hormone receptor Rev-erba, a target for which m…”
BackgroundGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss
Collin, G. B., Gogna, N., Chang, B., Damkham, N., Pinkney, J., Hyde, L. F., Stone, L. V., Naggert, J. Κ., Nishina, P. M., & Krebs, M. P. (2020) · Cells · doi:10.3390/cells9040931 · Cited by 105
“Causality was confirmed by phenotypic rescue of the rd7-associated phenotypes by in vivo electroporation of a wild-type Nr1d1 expression construct [464].”
BackgroundOcular Clocks: Adapting Mechanisms for Eye Functions and Health
Felder‐Schmittbuhl, M., Buhr, E. D., Dkhissi‐Benyahya, O., Hicks, D., Peirson, S. N., Ribelayga, C., Sandu, C., Spessert, R., & Tosini, G. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24957 · Cited by 102
Li, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-0134-z · Cited by 68
“Genetic modi fi ers play a key role in modulating disease onset, progression, and clinical outcome by either enhancing or suppressing disease [24, 40].”
BackgroundSelf-citation
Metadata
- Authors
- Cruz, N. M., Yuan, Y., Leehy, B. D., Baid, R., Kompella, U., DeAngelis, M. M., Escher, P., & Haider, N. B.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- University of Nebraska Medical Center (US)
- University of Colorado Anschutz (US)
- University of Utah (US)
- Institut de Recherche en Opthalmologie (CH)
- Corresponding author
- Haider, Neena B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-31
- Volume
- 9
- Issue
- 1
- Pages
- e87942
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3909326
- OpenAlex
- W2031568258
- Cited by
- 47
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 3
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open Access CRIS of the University of Bern
- Funders
- Massachusetts Lions Eye Research Fund
- Edward N. and Della L. Thome Memorial Foundation
- Hope For Vision
- National Institutes of Health
- U.S. Public Health Service (P20-RRO18788-03)
- National Eye Institute (RO1EY017653-01A2S1, RO1EY017653, R01EY017653, T32EY007145)
- National Center for Research Resources
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- NR1D1, NR2E3, retinal degeneration, nuclear receptors, retinitis pigmentosa, enhanced S-cone syndrome, genetic modifiers, gene therapy, transcriptional regulation, retinal disease therapy
- MeSH terms
- Animals, Humans, Mice, Transgenic, Retinal Degeneration, Retinitis Pigmentosa, Vision Disorders, Genetic Therapy, Eye Diseases, Hereditary, Mice, Nuclear Receptor Subfamily 1, Group D, Member 1, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modifier Genes as Therapeutics: The Nuclear Hormone Receptor Rev Erb Alpha (Nr1d1) Rescues Nr2e3 Associated Retinal Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0087942
- The paper
- Cruz, N. M., Yuan, Y., Leehy, B. D., Baid, R., Kompella, U., DeAngelis, M. M., Escher, P., & Haider, N. B. (2014). Modifier Genes as Therapeutics: The Nuclear Hormone Receptor Rev Erb Alpha (Nr1d1) Rescues Nr2e3 Associated Retinal Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0087942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.